VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods, tell me about this news today

VivoSim Labs, Inc. issued a statement welcoming and celebrating the U.S. Food and Drug Administration’s (FDA) updated regulatory framework that formally allows and encourages greater use of non-animal testing methods.

GlobeNewswire

Background of the Regulatory Change The FDA updated regulations governing nonclinical safety evaluations for drugs and biological products. The rule officially recognizes New Approach Methodologies (NAMs)such as 3D cell-based assays, organs-on-chips, and advanced computational modelsas valid alternatives to traditional animal testing in preclinical evaluations. This regulatory alignment follows broader federal initiatives, including the FDA Modernization Act 2.0, aimed at reducing reliance on animal models in favor of scientifically predictive, human-relevant systems.

FDA+ 2

VivoSim Labs’ Position and Technology VivoSim Labs, based in San Diego, specializes in providing three-dimensional human cellular tissue modelsparticularly for liver and intestinal toxicology. Because drug-induced liver injury (DILI) and gastrointestinal toxicities are among the leading drivers of drug failure during clinical phases, the company provides these NAMs to identify adverse toxicological profiles earlier in discovery.

GlobeNewswire+ 1

Key Takeaways from the Announcement

• Financial and Trial Efficiency: VivoSim highlighted that animal models frequently fail to predict human-specific toxicities, causing pharmaceutical sponsors to spend $50 million to $200 million advancing candidates that ultimately fail in clinical trials.

  StreetInsider

• Potential Reduction in Development Costs: Executive leadership noted that improving early predictive accuracy could dramatically increase clinical trial success rates (which historically hover around 8–10%), potentially cutting the massive aggregate cost of bringing new therapeutics to market by up to half.

  StreetInsider

• Commercial Momentum for NAMs: The company anticipates accelerated commercial adoption of its 3D human tissue platforms now that regulatory pathways officially clarify and accommodate non-animal submission data for safety profiling.

  Stock Titan